Skip to content
Swiss Observer

Roche breast cancer treatment wins US approval

The US Food and Drug Administration has approved Roche’s oral breast cancer treatment giredestrant in combination with everolimus for certain patients with advanced disease. Roche expects the drug to contribute to sales from 2027.

AINovember 18, 2026About our editorial process
Roche breast cancer treatment wins US approval
AISWI swissinfo.ch

The FDA has cleared Roche’s Wilserdly for a defined group of patients with advanced breast cancer, opening the US market to the Swiss pharmaceutical company’s new oral treatment. The drug, whose generic name is giredestrant, will be used with everolimus for cancers that are oestrogen receptor-positive, HER2-negative and carry an ESR1 gene mutation.

The approval covers locally advanced or metastatic disease. The FDA says the treatment is intended for patients whose cancer returned during or after adjuvant endocrine therapy, or progressed while they were receiving at least one endocrine therapy for metastatic disease. These criteria target patients whose cancer has continued to advance despite hormone-based treatment.

The authorisation marks Wilserdly’s first marketing approval. Roche’s Basel-based US subsidiary, Genentech, developed the treatment. The company expects the launch to begin contributing to sales from next year, with 2027 set to be its first full year on the market.

Target Resistant Disease With an Oral Option

Roche reports a 62% improvement on a key disease outcome for the combination of Wilserdly and everolimus compared with standard endocrine therapy plus everolimus. The company says the treatment significantly delayed disease progression or reduced mortality. The finding supports the drug’s role for patients whose cancer has advanced despite endocrine treatment.

The tablet-based regimen gives patients an entirely oral option. Roche chief medical officer Levi Garraway said that “for patients with advanced breast cancer harbouring an ESR1 gene mutation, the development of resistance to hormone therapy remains a major challenge, often requiring more intensive treatment”. He described Wilserdly as a treatment patients can continue from home.

The FDA prescribing information includes warnings and precautions, particularly concerning embryo-foetal toxicity. The approval therefore comes with defined use conditions and safety guidance for clinicians. Roche pharmaceuticals chief Teresa Graham called the authorisation a decisive step in managing aggressive, treatment-resistant breast cancer, following decades of the company’s work in oncology.

Weigh the Sales Forecasts and Price

Analysts see a substantial commercial opportunity, but their peak-sales estimates differ sharply. Urban Fritsche of Zurich Cantonal Bank estimates Wilserdly could generate up to CHF 14 billion in sales at its peak in 2033. The consensus forecast is CHF 4.2 billion. For the nearer term, analysts expect revenue of $500 million to $600 million, a range Roche says is in line with its expectations.

Roche has told AWP that Wilserdly carries a US list price of $22,500 per month. The company says that figure will not necessarily match what patients pay, because insurance coverage and public assistance schemes can affect their out-of-pocket costs. Royal Bank of Canada says the price is comparable with Eli Lilly’s Inluriyo, or imlunestrant, and below AstraZeneca’s Etcamah, or camizestrant.

For scale, Roche reported CHF 61.52 billion in revenue in 2025, including CHF 48 billion from pharmaceuticals. The company expects Wilserdly to contribute to sales from next year, with 2027 its first full year on the market.

Put the Approval in a Global Context

Breast cancer affects millions of people worldwide each year, and hormone-dependent disease accounts for most cases. Figures from the World Health Organization cited by Roche put annual diagnoses at 2.3 million and deaths at 670,000. Hormone-dependent cancers make up 70% of breast cancer cases, the group most relevant to Wilserdly’s target biology.

The Swiss company’s new US approval places a Basel-developed pharmaceutical group in a competitive market alongside treatments from US-based Eli Lilly and UK-based AstraZeneca. Roche says the drug’s first full year of sales will be 2027, while analysts’ estimates point to a potentially much larger contribution at peak.

The immediate significance for Roche is commercial as well as clinical: the company can now launch Wilserdly in the United States for the approved patient group, at a stated list price of $22,500 per month. Roche’s forecasts and the differing analyst projections will shape expectations as the treatment enters its first full year on the market.